246 related articles for article (PubMed ID: 30824788)
1. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
Chin KL; Ofori-Asenso R; Si S; Hird TR; Magliano DJ; Zoungas S; Liew D
Sci Rep; 2019 Mar; 9(1):3256. PubMed ID: 30824788
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Cai X; Shi L; Yang W; Gu S; Chen Y; Nie L; Ji L
J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
Sabale U; Ekman M; Granström O; Bergenheim K; McEwan P
Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus.
Abushanab D; Liew D; Marquina C; Al-Badriyeh D; Ademi Z
Endocr Pract; 2022 Jan; 28(1):16-24. PubMed ID: 34389513
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
Shao H; Zhai S; Zou D; Mir MU; Zawadzki NK; Shi Q; Liu S; Shi L
Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
[TBL] [Abstract][Full Text] [Related]
9. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Elsisi GH; Anwar MM; Khattab M; Elebrashy I; Wafa A; Elhadad H; Awad M; Carapinha JL
J Med Econ; 2020 Aug; 23(8):908-914. PubMed ID: 32364032
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
Parizo JT; Goldhaber-Fiebert JD; Salomon JA; Khush KK; Spertus JA; Heidenreich PA; Sandhu AT
JAMA Cardiol; 2021 Aug; 6(8):926-935. PubMed ID: 34037681
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
[TBL] [Abstract][Full Text] [Related]
12. First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis.
Abushanab D; Al-Badriyeh D; Liew D; Ademi Z
Curr Probl Cardiol; 2022 Jun; 47(6):100852. PubMed ID: 33992426
[TBL] [Abstract][Full Text] [Related]
13. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain].
Abad Paniagua EJ; Casado Escribano P; Fernández Rodriguez JM; Morales Escobar FJ; Betegón Nicolás L; Sánchez-Covisa J; Brosa M
Aten Primaria; 2015 Oct; 47(8):505-13. PubMed ID: 25555492
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
Van der Linden N; Van Olst S; Nekeman S; Uyl-de Groot CA
Diabet Med; 2021 Apr; 38(4):e14371. PubMed ID: 32745279
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
Liao CT; Yang CT; Toh HS; Chang WT; Chang HY; Kuo FH; Lee MC; Hua YM; Tang HJ; Strong C; Ou HT
Cardiovasc Diabetol; 2021 Oct; 20(1):204. PubMed ID: 34627231
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
van Haalen HG; Pompen M; Bergenheim K; McEwan P; Townsend R; Roudaut M
Clin Drug Investig; 2014 Feb; 34(2):135-46. PubMed ID: 24243529
[TBL] [Abstract][Full Text] [Related]
18. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
20. Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
Parker ED; Wittbrodt ET; McPheeters JT; Frias JP
Diabetes Obes Metab; 2019 Feb; 21(2):227-233. PubMed ID: 30101553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
